Previous investigations have demonstrated that silencing of ER in ER+ MCF-7 breast cancer cells leads to acquisition of endocrine resistance and mesenchymal features, which contribute to tumor aggressiveness and metastatic ability [6, 29]. Here, ESR1 is linked to breast cancer.